Diagnosis, prevention and treatment of ulcerative colitis, and clinical
subtypes thereof, using histone H1
    1.
    发明授权
    Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1 失效
    使用组蛋白H1诊断,预防和治疗溃疡性结肠炎及其临床亚型

    公开(公告)号:US6074835A

    公开(公告)日:2000-06-13

    申请号:US837058

    申请日:1997-04-11

    IPC分类号: G01N33/68 G01N33/564

    CPC分类号: G01N33/6875 G01N2800/065

    摘要: The present invention provides a method of diagnosing ulcerative colitis (UC) in a subject suspected of having inflammatory bowel disease by by obtaining a sample from the individual; contacting the sample with human histone H1, or pANCA-reactive fragment thereof, under conditions suitable to form a complex of human histone H1, or pANCA-reactive fragment thereof, and antibody to human histone H1; and detecting the presence or absence of the complex, where the presence of the complex indicates that the individual has UC. The invention also provides related methods of diagnosing a perinuclear anti-neutrophil cytoplasmic antibody positive (pANCA-positive) clinical subtype of UC in a patient with UC. In addition, the invention further provides methods of determining susceptibility to UC in an individual. The invention further provides methods of inducing tolerance in a pANCA-positive patient with UC by administering an effective dose of histone H1, or tolerogenic fragment thereof, to the pANCA-positive patient with UC. Compositions of histone H1, or fragment thereof, combined with a tolerogizing molecule also are provided.

    摘要翻译: 本发明提供一种通过从个体获得样品来诊断疑似患有炎症性肠病的受试者的溃疡性结肠炎(UC)的方法; 在适于形成人组蛋白H1或其pANCA反应性片段的复合物和人组蛋白H1的抗体的条件下,将样品与人组蛋白H1或其pANCA反应性片段接触; 并检测复合物的存在或不存在,其中复合物的存在表明个体具有UC。 本发明还提供了在UC患者中诊断UC的核周抗中性粒细胞胞质抗体阳性(pANCA阳性)临床亚型的相关方法。 此外,本发明还提供了确定个体对UC的易感性的方法。 本发明进一步提供了通过向具有UC的pANCA阳性患者施用有效剂量的组蛋白H1或其耐受性片段来诱导具有UC的pANCA阳性患者的耐受性的方法。 还提供组蛋白H1或其片段的组合物与耐受性分子组合。

    METHODS OF ASSESSING CROHN'S DISEASE PATIENT PHENOTYPE BY I2, OMPC AND ASCA SEROLOGIC RESPONSE
    4.
    发明申请
    METHODS OF ASSESSING CROHN'S DISEASE PATIENT PHENOTYPE BY I2, OMPC AND ASCA SEROLOGIC RESPONSE 审中-公开
    通过I2,OMPC和ASCA行为反应来评估冠心病患者的方法

    公开(公告)号:US20120208212A1

    公开(公告)日:2012-08-16

    申请号:US13312960

    申请日:2011-12-06

    IPC分类号: G01N33/566

    摘要: The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.

    摘要翻译: 本发明提供一种诊断或预测克罗恩病临床亚型易感性的方法,其通过测定受试者中IgA抗-I2抗体的存在或不存在,其中IgA抗-I2抗体的存在表明 该受试者具有克罗恩病的临床亚型。 在一个实施方案中,通过进一步确定受试者中NOD2变体,抗酿酒酵母抗体(ASCA),IgA抗OmpC抗体或核周抗中性粒细胞胞质抗体(pANCA)的存在或不存在来实施本发明的方法 )。 本发明的方法可以用于诊断或预测对克罗恩病的临床亚型的易感性,例如纤维狭窄亚型,特征在于需要小肠手术的亚型或特征在于不存在溃疡特征的亚型 结肠炎。

    Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease
    5.
    发明授权
    Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease 有权
    用于诊断和治疗克罗恩病的CBir1抗原应答的表征

    公开(公告)号:US08153443B2

    公开(公告)日:2012-04-10

    申请号:US12599549

    申请日:2008-05-09

    摘要: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.

    摘要翻译: 本发明通过确定遗传变异体的存在或不存在来提供诊断或预测克罗恩病敏感性的方法。 在一个实施方案中,本发明提供了通过确定抗Cbir1反应性的存在或不存在以及是否存在TLR5风险变体来诊断和/或预测个体中克罗恩病易感性的方法。 在另一个实施方案中,本发明通过确定NFκB1单倍型H3和/或ASCA表达的存在或不存在来提供诊断克罗恩病的方法。 在另一个实施方案中,本发明通过确定Cbir1特异性外周血T细胞增殖的存在或不存在来提供诊断克罗恩病的方法。

    CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE
    7.
    发明申请
    CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE 有权
    CBIR1抗原反应诊断和治疗高血糖病的特征

    公开(公告)号:US20100284999A1

    公开(公告)日:2010-11-11

    申请号:US12599549

    申请日:2008-05-09

    摘要: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.

    摘要翻译: 本发明通过确定遗传变异体的存在或不存在来提供诊断或预测克罗恩病敏感性的方法。 在一个实施方案中,本发明提供了通过确定抗Cbir1反应性的存在或不存在以及是否存在TLR5风险变体来诊断和/或预测个体中克罗恩病易感性的方法。 在另一个实施方案中,本发明通过确定NFκB1单倍型H3和/或ASCA表达的存在或不存在来提供诊断克罗恩病的方法。 在另一个实施方案中,本发明通过确定Cbir1特异性外周血T细胞增殖的存在或不存在来提供诊断克罗恩病的方法。